AusBiotech is the leading Australian industry body representing and advocating for organisations doing business in and with the global life sciences economy. AusBiotech marked 30 years since the industry organisation was founded on 28 December 2015. As part of the 2016 celebrations of this event, the organisation is publishing ’30 success stories in 30 days’ in…

Notice of 2015 Annual General Meeting

Dr Douglas Millar, Chief Scientific Officer of Genetic Signatures, has recently released a paper describing his work on directed enzyme evolution in collaboration with Dr Philipp Holliger, of the MRC laboratory for Molecular Biology in Cambridge UK. The paper “A polymerase engineered for bisulfite sequencing” published in Nucleic Acids Res. describes 5D4, an engineered DNA…

Molecular diagnostics (MDx) company Genetic Signatures will exhibit and present scientific data at the 43rd Annual Scientific Meeting and Trade Exhibition of the Australian Society for Microbiology which will be held on the 12th to 15th of July 2015 in Canberra, Australia. Dylan Warby, Genetic Signatures Sales and Marketing Manager, will present a scientific poster titled Comparison…

Alan Kohler of the Eureka report recently interviewed Genetic Signatures CEO Dr John Melki. Dr Melki spoke about the history of Genetic Signatures and his own 12-year involvement with the company, and 20 years experience using the tools that form the basis of its 3base™ technology. Alan queried John about Genetic Signatures products, financial results…

Molecular diagnostics (MDx) company Genetic Signatures will exhibit and present scientific data at the 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), which will be held on 25 – 28 April 2015 in Copenhagen, Denmark. Dr Doug Millar, Genetic Signatures Chief Scientific Officer, will present a scientific poster titled “Comparison of the Efficiency…

Press Release

Press Release

Genetic Signatures has issued a Supplementary Prospectus to extend the closing date of its IPO to 5.00pm (AEDT) on 20 March 2015. This Supplementary Prospectus supplements, and must be read together with, the Prospectus dated 7 November 2014 (“Prospectus”) relating to an offer of Shares by the Company. The prospectus and supplementary prospectus may be…

Exciting Australian Biotech offers Institutional & Retail Shareholders Access to Global $5.3B Molecular Diagnostics Market Sydney, Australia – 18 November 2014: Genetic Signatures Ltd has launched its prospectus offering institutional and retail investors the opportunity to invest in the exciting growing global molecular diagnostics market prior to the Company’s listing on the Australian Stock Exchange on…